Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Verastem Inc. (VSTM) Prices 7.78M Share Common Offerings at $4.50/Sh
-
Verastem Oncology Announces Pricing of Public Offering of Common Stock
-
Five Star Quality Care (FVE) PT Lowered to $3 at Cantor Fitzgerald
-
Verastem (VSTM) Commences $35M Common Stock Offering
-
Verastem Oncology Announces Public Offering of Common Stock
-
ProPhotonix Expands Red Laser Diodes with 638nm - STKR - ProPhotonix Limited
-
Cantor Asks if Athenahealth (ATHN) Efforts to Drive Growth is as Valuable as Elliott Offer
-
The Currency of Tomorrow is Here - Makor Group Launches a New Crypto Brokerage Firm: Enigma Securities
-
Aetna (AET) Trump Proposal Unlikely To Impact Managed Care - Cantor Fitzgerald
-
Synergy Pharmaceuticals (SGYP) PT Lowered to $6 at Cantor Fitzgerald
-
Celsion Corporation Reports First Quarter 2018 Financial Results and Provides Business Update
-
CareTrust REIT (CTRE) PT Raised to $17 at Cantor Fitzgerald
-
Supernus Pharmaceuticals (SUPN) PT Raised to $55 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight on Ocular Therapeutix (OCUL) Following 1Q
-
Cantor Fitzgerald Remains Bullish on Mallinckrodt (MNK) Following 1Q
-
7 Key Points In Valeant Pharma's (VRX) Turnaround - Cantor Fitzgerald
-
Gartner (IT) PT Raised to $148 at Cantor Fitzgerald
-
Cantor Fitzgerald Upgrades Arrowhead Research (ARWR) to Overweight
-
Cerus (CERS) PT Raised to $7 at Cantor Fitzgerald
-
CytoSorbents Reports Strong First Quarter 2018 Financial Results
-
Valeant Pharmaceuticals (VRX): 'A Turnaround For The Ages' - Cantor Fitzgerald
-
Cantor Fitzgerald Downgrades Egalet Ltd (EGLT) to Neutral
-
Endo International (ENDP) Needs to Show Upward Inflection in Earnings for Cantor to Become More Positive
-
Cantor Fitzgerald Bullish on Spark Therapeutics (ONCE) Ahead of Important Hemophilia Catalysts
-
Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
-
Athenahealth (ATHN) Offer from Elliot 'seems fair' - Cantor
-
BioDelivery Sciences (BDSI) New CEO Removes One Overhang - Cantor Fitzgerald
-
FMI Corporation Advises IEA Services LLC in Merger With M III Acquisition Corp.
-
Form 4 BGC Partners, Inc. For: May 03 Filed by: CANTOR FITZGERALD, L. P.
-
HMS Holdings (HMSY) PT Raised to $19 at Cantor Fitzgerald on 1Q Report; 'Positioned to Reach FY18 Financial Objectives'
-
The Ensign Group Inc. (ENSG) PT Raised to $35 at Cantor Fitzgerald
-
Cantor Fitzgerald Downgrades U.S. Physical Therapy (USPH) to Neutral
-
MSCI Inc. (MSCI) PT Raised to $166 at Cantor Fitzgerald
-
TherapeuticsMD (TXMD) PT Lowered to $26 at Cantor Fitzgerald
-
Ex-Cantor Fitzgerald bond trader acquitted in U.S. of fraud
-
U.S. prosecutors dealt dual setbacks in mortgage bond fraud crackdown
-
MasterCard (MA) PT Raised to $213 at Cantor Fitzgerald
-
Jack Henry (JKHY) PT Raised to $134 at Cantor Fitzgerald
-
Cerner (CERN) PT Lowered to $70 at Cantor Fitzgerald
-
Zoetis Inc. (ZTS) PT Raised to $98 at Cantor Fitzgerald Following Q1 Earnings Report
-
Karyopharm Therapeutics (KPTI) PT Raised to $25 at Cantor Fitzgerald
-
Fidelity National Information Services (FIS) PT Raised to $111 at Cantor Fitzgerald
-
Rigel Pharmaceuticals (RIGL) PT Raised to $9 at Cantor Fitzgerald
-
Fiserv (FISV) PT Raised to $70 at Cantor Fitzgerald
-
Cantor Fitzgerald Upgrades Aetna (AET) to Overweight Citing More Compelling Risk/Reward
-
Cantor Remains Sidelined on HealthStream (HSTM), Says Top Line Growth Outllok Remains Modest
-
Cantor Stays Positive on Jazz Pharmaceuticals (JAZZ), Sees Purchase of PRV As Potentially Useful Tool for Asset Development
-
AxoGen, Inc. (AXGN) PT Raised to $45 at Cantor Fitzgerald
-
Allergen (AGN) PT Lowered to $180 at Cantor Fitzgerald
-
Spark Therapeutics (ONCE) PT Raised to Street High $103 at Cantor Fitzgerald

